• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aerie Pharmaceuticals, Inc. - Common Stock (NQ:AERI)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 18, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aerie Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 Next >
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business
November 22, 2022
From Alcon Inc. Investors
Via Business Wire
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 03, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI
October 14, 2022
From Kahn Swick & Foti, LLC
Via Business Wire
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
October 04, 2022
Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month. 
Via MarketBeat
Topics Stocks
Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options
September 13, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI
August 24, 2022
From Kahn Swick & Foti, LLC
Via Business Wire
AERI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Aerie Pharmaceuticals, Inc. Is Fair to Shareholders
August 24, 2022
From Halper Sadeh LLP
Via Business Wire
Aerie Pharmaceuticals (NASDAQ: AERI) Enters into Agreement to be Acquired by Alcon (NYSE: ALC) for $770 Million
August 23, 2022
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) is engaged within the research, development and commercialization of ophthalmic therapies for the treatment of 
Via Spotlight Growth
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
August 22, 2022
From Alcon Inc. Investors
Via Business Wire
Aerie Pharmaceuticals Announces New Employee Inducement Grant
August 15, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
August 04, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease
August 01, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET
July 28, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces New Employee Inducement Grant
July 08, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET
May 25, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease
May 24, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
May 05, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022 at 5:00 p.m. ET
April 28, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces Presentations at the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, Colorado, May 1-4, 2022
April 26, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., April 22-26, 2022
April 20, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. ET
April 06, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer
March 18, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
February 24, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Appoints Gary Sternberg, M.D., M.B.A. as Chief Medical Officer
February 24, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022 at 5:00 p.m. ET
February 17, 2022
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Reports Inducement Grant to Chief Executive Officer Under Nasdaq Listing Rule 5635(c)(4)
December 22, 2021
From Aerie Pharmaceuticals
Via Business Wire
Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer
December 16, 2021
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions
December 07, 2021
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
November 09, 2021
From Aerie Pharmaceuticals, Inc.
Via Business Wire
Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
November 04, 2021
From Aerie Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 Next >
Recent Quotes
View More
Symbol Price Change (%)
GOOG  251.66
+5.47 (2.22%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap